Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia

DSpace Repository

Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia

Author: Kampa-Schittenhelm, Kerstin Maria; Frey, Julia; Haeusser, Lara A.; Illing, Barbara; Pavlovsky, Ashly A.; Blumenstock, Gunnar; Schittenhelm, Marcus Matthias
Tübinger Autor(en):
Kampa-Schittenhelm, Kerstin Maria
Frey, Julia
Haeusser, Lara A.
Illing, Barbara
Blumenstock, Gunnar
Schittenhelm, Marcus Matthias
Published in: Oncotarget (2017), Bd. 8, H. 47, S. 82897-82909
Verlagsangabe: Impact Journals Llc
Language: English
Full text: http://dx.doi.org/10.18632/oncotarget.19970
ISSN: 1949-2553
DDC Classifikation: 570 - Life sciences; biology
610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)